|
Market Cap (17-May) $1,668,273,536 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 76.34 |
EPS 1.09 |
NEU released this announcement to the ASX on 24 February 2023, 15:30. The announcement is not marked as price sensitive, and is 19 page(s) in length and 1.32MB in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.158% short sold according to ASIC data. It was ranked the 426th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Investor Presentation, 24 February 2023 | 24 February 2023, 15:30 |
| Neuren reports 2022 full-year results | 24 February 2023, 9:36 |
| Appendix 4E and 2022 full year accounts | 24 February 2023, 9:32 |
| Application for quotation of securities - NEU | 21 February 2023, 16:22 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 